瑞泰科技(002066.SZ)第三季度預盈1188.14萬元 同比增長42.57%
格隆匯10月10日丨瑞泰科技(002066.SZ)公佈,預計2021年度前三季度歸屬於上市公司股東的淨利潤3506.69萬元,同比增長202.62%;其中,第三季度歸屬於上市公司股東的淨利潤1188.14萬元,同比增長42.57%。
2021年1-9月,公司以實現高質量發展為導向,紮實推進改革創新、轉型升級等各項工作,實現收入和利潤的雙增長,1-9月份,實現營業收入34.04億元,同比增長12.93%,實現利潤總額11401萬元,同比增長69.76%,歸屬於上市公司股東的淨利潤3506.69萬元,同比增長202.62%。收入和利潤增長的主要原因是公司鋼鐵板塊和玻璃板塊實現較大增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.